ViroPharma Continues Development Of Subcutaneous Cinryze Despite Setback
This article was originally published in The Pink Sheet Daily
The specialty pharma announced Aug. 1 that it is halting a Phase IIb study of a subcutaneous formulation of Cinryze with Halozyme’s recombinant human hyaluronidase (rHuPH20) due to safety concerns. Meanwhile, it reported 22% sales growth year-over-year for its hereditary angioedema drug in the U.S.
You may also be interested in...
ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.
Schemes and funding to support growth in the life sciences and medtech sectors featured in the UK government’s spring budget on 3 March.
Entries are now open for the Global Generics & Biosimilars Awards 2021, which will take place in Milan, Italy on 10 November.